{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:32:52Z","timestamp":1793251972077,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jinf.2026.106874","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:11:19Z","timestamp":1791645079000},"page":"106874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infectious complications of treatment for acute lymphoblastic leukemia in adults: Is antifungal prophylaxis necessary? A single-center retrospective cohort study"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-6082","authenticated-orcid":false,"given":"Marco Aurelio","family":"D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5115-4757","authenticated-orcid":false,"given":"Andres","family":"Franceschi Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-092X","authenticated-orcid":false,"given":"Isabel H.","family":"Gonzalez-Bocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-6732","authenticated-orcid":false,"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2501-9182","authenticated-orcid":false,"given":"Leonardo","family":"Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-4280","authenticated-orcid":false,"given":"Christine J.","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-1482","authenticated-orcid":false,"given":"Seohyeon","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-7439","authenticated-orcid":false,"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jinf.2026.106874_bib1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000546381","article-title":"Treatment of older adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"149","author":"Mendez","year":"2026","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/hematology.2021000226","article-title":"Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?","volume":"2021","author":"Luskin","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"25","key":"10.1016\/j.jinf.2026.106874_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"386","author":"Fo\u00e0","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO clinical practice guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Ann Oncol"},{"issue":"42","key":"10.1016\/j.jinf.2026.106874_bib8","first-page":"1","article-title":"Innovative approaches to the management of acute lymphoblastic leukemia across the age spectrum","author":"Curran","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"24","key":"10.1016\/j.jinf.2026.106874_bib9","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1080\/14796694.2025.2556647","article-title":"How I treat Ph+ acute lymphoblastic leukemia","volume":"21","author":"Castro-Mollo","year":"2025","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.jinf.2026.106874_bib10","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/S2352-3026(24)00285-0","article-title":"Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia","volume":"11","author":"Aldoss","year":"2024","journal-title":"Lancet Haematol"},{"issue":"19","key":"10.1016\/j.jinf.2026.106874_bib11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jinf.2026.106874_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","article-title":"Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies","volume":"33","author":"Atkins","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"11","key":"10.1016\/j.jinf.2026.106874_bib13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/pathogens13110933","article-title":"Epidemiology of bacteremia in patients with hematological malignancies and hematopoietic stem cell transplantation and the impact of antibiotic resistance on mortality: data from a multicenter study in Argentina","volume":"13","author":"Herrera","year":"2024","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.jinf.2026.106874_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.idc.2019.02.006","article-title":"Fungal infections of the stem cell transplant recipient and hematologic malignancy patients","volume":"33","author":"Bays","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"30","key":"10.1016\/j.jinf.2026.106874_bib15","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7\u2009+\u20093 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"9398","key":"10.1016\/j.jinf.2026.106874_bib17","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jinf.2026.106874_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions\u2014practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"14","key":"10.1016\/j.jinf.2026.106874_bib19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-023-02115-4","article-title":"Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols","volume":"38","author":"Valtis","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jinf.2026.106874_bib22","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jinf.2026.106874_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jinf.2026.106874_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00277-005-1090-9","article-title":"FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia","volume":"84","author":"Specchia","year":"2005","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.jinf.2026.106874_bib27","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jinf.2026.106874_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jinf.2026.106874_bib29","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jinf.2026.106874_bib30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"32","key":"10.1016\/j.jinf.2026.106874_bib32","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO-25-00307","article-title":"Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed B-cell ALL: Alliance study A041703 cohort 1 results","volume":"43","author":"Wieduwilt","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jinf.2026.106874_bib33","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jinf.2026.106874_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jinf.2026.106874_bib35","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106874_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2026.2724605","article-title":"Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis","author":"Farag","year":"2026","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jinf.2026.106874_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01716-2","article-title":"Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jinf.2026.106874_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkv343","article-title":"Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit","volume":"71","author":"Doan","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.jinf.2026.106874_bib39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jinf.2026.106874_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106574","article-title":"Risk factors for invasive mould infections in adult patients with hematological malignancies and\/or stem cell transplant: a systematic literature review and meta-analysis","volume":"91","author":"Gras","year":"2025","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jinf.2026.106874_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cmi.2014.11.022","article-title":"Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey","volume":"21","author":"Trecarichi","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jinf.2026.106874_bib42","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/jcm14062055","article-title":"Integrating blinatumomab in the frontline treatment in B-cell acute lymphoblastic leukemia: a new era in therapeutic management","volume":"14","author":"Canichella","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jinf.2026.106874_bib43","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2026.106874_bib44","article-title":"2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies","volume":"51","author":"Sandherr","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"10.1016\/j.jinf.2026.106874_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-013-0171-4","article-title":"Febrile neutropenia in hematologic malignancies","volume":"8","author":"Keng","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1016\/j.jinf.2026.106874_bib46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326002008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326002008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:01:25Z","timestamp":1793250085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326002008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0163445326002008"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106874","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious complications of treatment for acute lymphoblastic leukemia in adults: Is antifungal prophylaxis necessary? A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106874"}}